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The genus Artemisia consists of about 500 species, occurring throughout the world. Some very important drug leads have been discovered
from this genus, notably artemisinin, the well known anti-malarial drug isolated from the Chinese herb Artemisia annua. The genus is also known
for its aromatic nature and hence research has been focussed on the chemical compositions of the volatile secondary metabolites obtained from
various Artemisia species. In the southern African region, A. afra is one of the most popular and commonly used herbal medicines. It is used to
treat various ailments ranging from coughs and colds to malaria and diabetes. Although it is one of the most popular local herbal medicines, only
limited scientific research, mainly focussing on the volatile secondary metabolites content, has been conducted on this species. The aim of this
review was therefore to collect all available scientific literature published on A. afra and combine it into this paper. In this review, a general
overview will be given on the morphology, taxonomy and geographical distribution of A. afra. The major focus will however be on the secondary
metabolites, mainly the volatile secondary metabolites, which have been identified from this species. In addition all of the reported biological
activities of the extracts derived from this species have been included as well as the literature on the pharmacology and toxicology. We aim at
bringing together most of the available scientific research conducted on this species, which is currently scattered across various publications, into
this review paper.
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Traditional Chinese Medicine (TCM) is a well-known and
well-studied research field. Many academic and pharmaceutical
institutions around the World fund research into TCM with the
aim of finding new pharmaceutical entities, establishing quality
control protocols and to prove the efficacy of these traditional
medicines. Compared to TCM, the traditional African medicine
research is lagging behind. One of the main reasons for this is
that the available information on medicinal plants is not always
well documented. Furthermore, Africa encompasses a huge area
with diverse cultures and languages, which makes sharing of
information difficult. The lack of well-funded research institu-
tions or pharmaceutical companies on the continent is also
adding to the problem. African researchers should therefore aim
at establishing their own “Traditional AfricanMedicine” (TAM),
which on the long run should bring to Africa the same
economical and social benefits that TCM has brought to
China. In order to achieve this goal, it would be extremely
beneficial to the cause if one can identify a flagship species
which will epitomize the end goal of establishing a TAM. For
this reason, we have decided to review most of the scientific
literature available on the endemic Artemisia afra Jacq.
(Asteraceae) species to establish if it might have the same
medicinal potential as the Chinese A. annua species.
Artemisia afra is one of the most popular and commonly
used herbal medicines in southern Africa. However, only
limited research has been conducted on this species. According
to a recent publication by Van Wyk (2008), only 42 scientific
publications and 2 patents related to A. afra are available of
which 27 publications and 1 patent were published between
2001 to 2008. This indicates that interest in A. afra has in-
creased significantly during recent years, prompting us to gather
all available research on A. afra and combine it into this review
paper. We could not find any previous reviews written on this
species and therefore we thought it important to take stock of
what has been done in the past, in order to provide a solid
foundation and direction to any future research that may be
conducted on this species.
2. Botanical aspects
2.1. Morphology
Artemisia afra is a perennial woody shrub, which grows up
to 2 m tall with a leafy, hairy and ridged stem (Van Wyk et al.,
1997). Its leaves are of soft texture, dark green on the adaxial
surface and a lighter green on the abaxial surface, reaching a
length of 8 cm and a width of 4 cm. Artemisia afra blossomsfrom January to June, producing yellow, butter-coloured
flowers with abundant bracts (Hilliard, 1977). The plant has
an easily identifiable aromatic odour and smells pungent and
sweet after bruising. The fruit is approximately 1 mm in length,
covered with a silvery-white coating and the shape is slightly
3-angled and curved. In winter, the branches rapidly regen-
erate from the base directly after dying back (Hilliard, 1977;
Van Wyk et al., 1997).
2.2. Taxonomy
Artemisia afra is classified into Kingdom: Plantae, Division:
Mannoliphyta, Class: Magnoliopsida, Sub-class: Asteridae,
Order: Asterales, Family: Asteraceae, Genus: Artemisia and
Species: Artemisia afra. The genus name Artemisia was derived
from the name of the Greek goddess of hunting, Artemis
(Jackson, 1990).
2.3. Distribution
Artemisia afra occurs in the mountain regions of Kenya,
Tanzania, Uganda and as far north as Ethiopia. It is also widely
distributed in southern Africa, such as South Africa, Namibia,
and Zimbabwe. In South Africa, it grows in the northern
provinces of Gauteng and Limpopo along the eastern parts of
South Africa, including Swaziland and Lesotho, to the Western
Cape in the south. It is also abundantly found in KwaZulu-Natal
province from the coast to the Drakensberg (Van Wyk et al.,
1997; Hilliard, 1977) at altitudes of 20 to 2440 m on damp
slopes, along streamsides and forest margins.
3. Ethnopharmacology and utilization
The many different common or local names describing this
plant may be ascribed to the widespread use by different ethnic
groups (Watt and Breyer-Brandwijk, 1932). In the Xhosa
language it is known as “Umhlonyane”, the Zulu language
“Mhlonyane”, in Sotho “Lanyana”, Tswana “Lengana”, English
“African wormwood” and in Afrikaans “Wilde als”. It is usually
employed for treating a variety of ailments such as coughs, colds,
headaches, chills, dyspepsia, loss of appetite, gastric derange-
ments, colic, croup, whooping-cough, gout, asthma, malaria,
diabetes, bladder and kidney disorders, influenza, convulsions,
fever, heart inflammation, rheumatism and is also used as a
purgative (Watt and Breyer-Brandwijk, 1932; Thring and Weitz,
2006). These uses indicate that A. afra possesses antiviral, anti-
bacterial and anti-inflammatory activities.
Many different preparations of this plant are employed to
treat the various symptoms and ailments. A syrup prepared from
Table 1
Volatile secondary metabolites identified in Artemisia afra.
Component Author
Monoterpenoids
artemisia alcohol Gavarry (1977); Chagonda et al. (1999);
Viljoen et al. (2006)
artemisia ketone Gavarry (1977); Moody et al. (1994);
Chagonda et al. (1999); Viljoen et al. (2006);
Asekun et al. (2007); Vagionas et al. (2007)
artemisyl acetate Worku and Rubiolo (1996); Chagonda et al. (1999);
Viljoen et al. (2006)
ascaridole Viljoen et al. (2006)
azulene Do Vale (1963)
borneol Do Vale (1963); Mwangi et al. (1995);
Chagonda et al. (1999); Muyima et al. (2002);
Viljoen et al. (2006); Asekun et al. (2007)
bornyl acetate Do Vale (1963); Chagonda et al. (1999);
Viljoen et al. (2006)
camphene Do Vale (1963); Chagonda et al. (1999);
Muyima et al. (2002); Viljoen et al. (2006)
camphor Do Vale (1963); Libbey and Sturtz (1989);
Graven et al. (1992); Chagonda et al. (1999);
Burits et al. (2001); Muyima et al. (2002);
Viljoen et al. (2006); Asekun et al. (2007);
Vagionas et al. (2007)
cis-carveol Chagonda et al. (1999)
caryophylla-2(12),6(13)-
dien-5-one
Viljoen et al. (2006)
cis-chrysanthenol Viljoen et al. (2006)
chrysanthenone Viljoen et al. (2006)
cis-chrysanthenyl
acetate
Viljoen et al. (2006)
1,8-cineole Do Vale (1963); Gavarry (1977); Libbey and Sturtz
(1989); Graven et al. (1992); Moody et al. (1994);
Mwangi et al. (1995); Chagonda et al. (1999);
Muyima et al. (2002); Viljoen et al. (2006);
Asekun et al. (2007); Vagionas et al. (2007)
cumin alcohol Viljoen et al. (2006)
dehydro carvyl acetate Viljoen et al. (2006)
dehydro-1,8-cineole Chagonda et al. (1999); Viljoen et al. (2006)
dehydrosabinaketone Viljoen et al. (2006)
cis-2,7-dimethyl-4-
octene-2,4-diol
Moody et al. (1994)
cis-1,2-epoxy-
terpinen-4-ol
Viljoen et al. (2006)
α-fenchene Chagonda et al. (1999)
geraniol Asfaw et al. (2005)
4α-hydroxy achipendol Viljoen et al. (2006)
4β-hydroxy achipendol Viljoen et al. (2006)
isoamyl isovalerate Viljoen et al. (2006)
isopiperitone Viljoen et al. (2006)
lavandulol Viljoen et al. (2006)
lavanduyl acetate Viljoen et al. (2006)
limonene Do Vale (1963); Chagonda et al. (1999);
Viljoen et al. (2006)
linalool Asfaw et al. (2005); Viljoen et al. (2006)
linalool acetate Muyima et al. (2002)
trans-linalool oxide
furanoid form
Viljoen et al. (2006)
trans-p-menth-2,8-
dien-1-ol
Viljoen et al. (2006)
trans-p-menth-1(7),
8-dien-2-ol
Viljoen et al. (2006)
cis-p-menth-2-en-1-ol Chagonda et al. (1999); Viljoen et al. (2006)
trans-p-menth-2-en-1-ol Viljoen et al. (2006)
p-mentha-1,4-dien-7-ol Viljoen et al. (2006)
(continued on next page)
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tions can be applied as a lotion to bathe hemorrhoids and for
earache. An infusion of leaves or roots of this species is also
used for the treatment of diabetes in the Eastern Cape Province
of South Africa (Erasto et al., 2005; Mahop and Mayet, 2007).
Respiratory infections are treated through inhaling the vapour
from boiling leaves and this vapour is also used to treat mens-
trual chill. Fresh tips are inserted into the nose for colds and
headaches and into hollow teeth to treat toothache. The poultice
of the leaves can be applied to relieve neuralgia, to treat the
swellings in mumps and is placed on the abdomen to treat
infantile colic. It is also helpful to reduce colic by administering
a tincture made of the leaves wetted by brandy (Watt and
Breyer-Brandwijk, 1932).
Artemisia afra is also used as an infusion. Usually, a quarter
cup of fresh leaves is added to a cup of boiling water and the
infusion is allowed to draw for 10 min. The mixture is then
strained and the resulting infusion is sweetened with honey.
This preparation is taken orally for relief of most of the above-
mentioned ailments (Roberts, 1990).
The use of other medicinal plants or substances in com-
bination with A. afra is also documented in African ethnophar-
macology. In South Africa, preparations of A. afra are often
made in combination with brandy, sugar, ginger, thyme, rose-
mary, mint, chamomile, Osmitopsis asteriscoides or Eucalyptus
globulus. A combination of A. afra and E. globulus is employed
to treat influenza, and the infusion of the leaves and stems of
Lippia asperifolia and A. afra is used as a formula for fevers,
influenza, measles, and as a prophylactic against lung
inflammations (Watt and Breyer-Brandwijk, 1932). Decoctions
of the leaves of A. afra and Agrimonia bracteata are used for
colds in southern Africa while decoctions of Tetradenia riparia
and umhlonyane (Xhosa name for A. afra) with salt are used to
treat coughs in the Transkei region of the Eastern Cape Province
of South Africa (Hutchings et al., 1996).
4. Chemistry
A major problem for using this plant by traditional means is
claimed to be variations in the phytochemical composition
(Dube, 2006). The volatile components are easily lost during the
production of traditional preparations as was shown by Asfaw
et al. (2005). Eight sesquiterpenes were lost during hydrodis-
tillation, which aimed at simulating the traditional preparation
method. Most work focussed on the volatile secondary
metabolites obtained from A. afra, while only relatively few
publications reported on other types of secondary metabolites
identified in this plant. In the following sub-sections, secondary
metabolites identified from A. afra will be discussed with their
corresponding references.
4.1. Volatile secondary metabolites
Many different extraction methods have been employed to
isolate volatile secondary metabolites from A. afra. This
includes hydrodistillation (HD), microwave assisted extraction
(MAE), ultrasound assisted extraction (UAE) and liquid/
Table 1 (continued )
Component Author
p-mentha-1,8-dien-10-ol Viljoen et al. (2006)
cis-p-mentha-1-(7),
8-dien-2-ol Viljoen et al. (2006)
trans-p-meth-2-en-1-ol Chagonda et al. (1999)
p-menthatriene Asfaw et al. (2005)
2-methyl butyl isovalerate Viljoen et al. (2006)
myrcene Chagonda et al. (1999); Viljoen et al. (2006)
myrtenal Chagonda et al. (1999); Viljoen et al. (2006)
myrtenol Chagonda et al. (1999); Viljoen et al. (2006)
(E)-β-ocimene Chagonda et al. (1999); Viljoen et al. (2006)
(Z)-β-ocimene Viljoen et al. (2006)
β-phellandrene Muyima et al. (2002)
α-pinene Do Vale (1963); Graven et al. (1992);
Chagonda et al. (1999); Muyima et al. (2002);
Viljoen et al. (2006)
β-pinene Chagonda et al. (1999); Muyima et al. (2002);
Viljoen et al. (2006)
pinocarvone Viljoen et al. (2006)
trans- pinocarveol Viljoen et al. (2006)
piperitol Chagonda et al. (1999)
cis-piperitol Viljoen et al. (2006)
trans-piperitol Viljoen et al. (2006)
piperitone Viljoen et al. (2006)
trans-piperitone oxide Viljoen et al. (2006)
sabinaketone Viljoen et al. (2006)
sabinene Chagonda et al. (1999); Viljoen et al. (2006)
trans-sabinol Viljoen et al. (2006)
cis-sabinene hydrate Chagonda et al. (1999); Viljoen et al. (2006)
trans-sabinene hydrate Chagonda et al. (1999); Viljoen et al. (2006)
sabinyl acetate Viljoen et al. (2006)
santolina alcohol Chagonda et al. (1999); Viljoen et al. (2006)
santolina triene Asfaw et al. (2005); Viljoen et al. (2006)
santolinyl acetate Viljoen et al. (2006)
terpinen-4-ol Mwangi et al. (1995); Chagonda et al.
(1999); Viljoen et al. (2006)
α-terpinene Chagonda et al. (1999); Muyima et al.
(2002); Viljoen et al. (2006)
γ-terpinene Chagonda et al. (1999); Viljoen et al. (2006)
4-terpineol Burits et al. (2001)
α-terpineol Chagonda et al. (1999); Viljoen et al. (2006)
δ-terpineol Chagonda et al. (1999); Viljoen et al. (2006)
terpinolene Chagonda et al. (1999); Viljoen et al. (2006)
3-thujanone Muyima et al. (2002)
α-thujene Viljoen et al. (2006)
β-thujene Muyima et al. (2002)
α-thujone Libbey and Sturtz (1989); Graven et al. (1992);
Chagonda et al. (1999); Viljoen et al. (2006);
Asekun et al. (2007); Vagionas et al. (2007)
β-thujone Libbey and Sturtz (1989); Graven et al. (1992);
Chagonda et al. (1999); Viljoen et al. (2006);
Asekun et al. (2007)
tricyclene Viljoen et al. (2006)
tricylene Chagonda et al. (1999)
cis-verbenol Viljoen et al. (2006)
yomogi alcohol Worku and Rubiolo (1996); Viljoen et al. (2006)
Sesquiterpenes
trans-α-bergamotol Viljoen et al. (2006)
bicycloelemene Viljoen et al. (2006)
bicyclogermacrene Chagonda et al. (1999); Viljoen et al. (2006)
α-bisabolol Viljoen et al. (2006)
δ-cadinene Chagonda et al. (1999); Viljoen et al. (2006)
caryophylladienol-II Viljoen et al. (2006)
chamazulene Burits et al. (2001)
davanone Burits et al. (2001)
Table 1 (continued )
Component Author
Sesquiterpenes
calamenene Chagonda et al. (1999)
caryophyllene oxide Viljoen et al. (2006)
trans-caryophyllene
oxide
Chagonda et al. (1999)
β-caryophyllene Chagonda et al. (1999); Viljoen et al. (2006)
α-copaene Chagonda et al. (1999); Viljoen et al. (2006)
β-costol Viljoen et al. (2006)
cubebol Viljoen et al. (2006)
epi-cubebol Viljoen et al. (2006)
1-epi-cubenol Viljoen et al. (2006)
(Z)-β-farnesene Viljoen et al. (2006)
germacrene Burits et al. (2001)
germacrene D Viljoen et al. (2006)
germacrene D-4-ol Chagonda et al. (1999); Viljoen et al. (2006)
globulol Viljoen et al. (2006)
α-humulene Viljoen et al. (2006)
intermedeol Chagonda et al. (1999)
intermediol Viljoen et al. (2006)
α-muurolol Viljoen et al. (2006)
t-muurolol Chagonda et al. (1999); Viljoen et al. (2006)
(E)-nerolidol Viljoen et al. (2006)
β-selinene Viljoen et al. (2006)
spathulenol Chagonda et al. (1999); Viljoen et al. (2006)
Others
artemisal Do Vale (1963)
berbenome Muyima et al. (2002)
cuminaldehyde Chagonda et al. (1999); Viljoen et al. (2006)
ar-curcumene Viljoen et al. (2006)
p-cymen-8-ol Chagonda et al. (1999); Viljoen et al. (2006)
p-cymene Chagonda et al. (1999); Viljoen et al. (2006)
4-hydroxy-4-
methylcyclohex-
2-enone
Viljoen et al. (2006)
isopropyl-3-
methylbenzene
Muyima et al. (2002)
p-isopropyl phenol Viljoen et al. (2006)
(Z)-jasmone Viljoen et al. (2006)
methyl linolenate Chagonda et al. (1999)
octadecanol Viljoen et al. (2006)
1-octen-3-ol Muyima et al. (2002); Viljoen et al. (2006)
tricosane Moody et al. (1994)
pentylbenzene Muyima et al. (2002)
Probably contained compounds
d-myrthenal Do Vale (1963)
umbellulone Do Vale (1963)
vetivazulene Do Vale (1963)
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2005). In this paper, the four extraction methods were tested
according to the yields and chemical composition of the oil. The
results demonstrated that l-CO2 and sc-CO2 gave the highest
yields (3.2%, v/w), followed by traditional HD (1.5%, v/w) and
MAE (1.3%, v/w). The lowest yield was achieved with UAE
(0.7% v/w). A comparison of the different fractions obtained
revealed that the yogomi alcohol content in the extracts
obtained from l-CO2 and sc-CO2, UAE, MAE and HD was
0.4%, 0.4%, 0.1%, 3.6% and 8.1%, respectively. In addition,
eight sesquiterpenes could only be detected in the sc-CO2,
l-CO2 and UAE, with relative percentage peak areas of
13%, 16% and 29%, respectively. These differences might
Table 2
Non-volatile secondary metabolites identified from Artemisia afra.
Component Author
Sesquiterpenes
β-farnesene Jakupovic et al. (1988)
Sesquiterpene lactones
Glaucolides
artemisia glaucolide Jakupovic et al. (1988)
eudesmaafraglaucolide Jakupovic et al. (1988); Kraft et al. (2003)
glaucolide 7 Jakupovic et al. (1988)
1α-hydroxyafraglaucolide Jakupovic et al. (1988)
1β-hydroxyafraglaucolide Jakupovic et al. (1988)
1α-hydroxyisoafraglaucolide Jakupovic et al. (1988)
12-hydroxy-α-cyperone Jakupovic et al. (1988)
Guaianolides
11,13-dehydromatricarin Kraft et al. (2003)
guaianolides 1 (2 derivatives) Jakupovic et al. (1988)
guaianolides 2 (6 derivatives) Jakupovic et al. (1988); Kraft et al. (2003)
guaianolides 3 (11 derivatives) Jakupovic et al. (1988); Kraft et al. (2003)
guaianolides 4 (2 derivatives) Jakupovic et al. (1988)
guaianolides 5 (3 derivatives) Jakupovic et al. (1988)
Others
Taurin Nkunya et al. (1992)
Triterpenes
α-amyrin Silbernagel et al. (1990)
β-amyrin Silbernagel et al. (1990)
friedelin Silbernagel et al. (1990)
squalene Jakupovic et al. (1988)
Long chain alkanes
cerylcerotinate Silbernagel et al. (1990)
nonacosane Silbernagel et al. (1990)
triacontane Goodson (1922)
6-triacontanone Nkunya et al. (1992)
wax ester Silbernagel et al. (1990)
wax ester (probably ceryl cerotate) Goodson (1922)
Coumarins
12-hydroxy-α-cyperone Jakupovic et al. (1988)
isofraxidin Jakupovic et al. (1988)
scopoletin Goodson (1922)
umbelliferone derivatives Bohlmann and Zdero (1972)
ouebrachitol Goodson (1922)
Organic acids
4-methylbenzoic acid Nkunya et al. (1992)
Glycosides
β-D-glucopyranoside Jakupovic et al. (1988)
Flavonoids
acacetin Kraft et al. (2003)
aglycon Wollenweber and Mann (1989)
apigenin Kraft et al. (2003)
chrysoeriol Kraft et al. (2003)
diosmetin Kraft et al. (2003)
genkwanin Kraft et al. (2003)
7-methoxyacacetin Kraft et al. (2003)
ouercetin Dube (2006)
kaempferol Dube (2006)
tamarixetin Kraft et al. (2003)
luteolin Dube (2006)
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compounds during the different methods of extraction.
For the identification of the major components in the oil, the
only reported analytical equipment used was gas chromato-
graphy coupled with either a flame ionization detector or mass
spectroscopy detector (Asfaw et al., 2005). Until now, 131
compounds have been identified from the oil of A. afra. Most of
these compounds can be classified as monoterpenes and ses-
quiterpenes. Several other components have also been found
during various other studies and are listed in Table 1 with the
corresponding references.
4.2. Non-volatile secondary metabolites
Early in the 1920s, Goodson (1922) found that A. afra con-
tained a wax-ester (probably ceryl cerotate), triacontane,
scopoletin and quebrachitol. During the following decades, a
few other publications reported on new secondary metabolites
identified from this species. Table 2 lists the non-volatile
secondary metabolites identified in A. afra and the correspond-
ing references.
5. Chemical variation in A. afra
The volatile secondary metabolite content in A. afra vary
frequently and is mainly due to the following factors:
(a) Geographical variation: The main components of the
volatile secondary metabolites identified in A. afra fluc-
tuate enormously in plants collected from different geo-
graphical regions. It is reported that artemisyl acetate
(24.4–32.1% of the total oil) was found to be the major
constituent in Ethiopian oil (Worku and Rubiolo, 1996)
while 1,8-cineole (67.4%) was found to be the major
constituent in Kenyan oil (Mwangi et al., 1995). In
Zimbabwean oil, α- and β-thujone (52%) was the major
constituent (Graven et al., 1992) while only α-thujone
(54.2%) was found to be the major constituent of South
African oil (Libbey and Sturtz, 1989).
Chagonda et al. (1999) found that the major constituents
of the volatile secondary metabolites from A. afra grown
in Zimbabwe, showed a large variation between culti-
vated and wild populations. The oil of wild populations
contained artemisia ketone (6.3–41.9%), 1,8-cineole
(0.1–27.9%), α-copaene/camphor (8.5–27.1%) and santo-
lina alcohol (3.1–10.1%) while the oil of the cultivated
populations mainly contained artemisia ketone (32.1–
34.8%), α-copaene/camphor (21.8–24.4%), 1,8-cineole
(10.9–15.7%) and santolina alcohol (2.7–8.0%). However,
the oil from plants cultivated at a different site, contained
mainly 1,8-cineole (22.5–29.3%), α-copaene/camphor
(6.2–21.3%), borneol (14.2–19.1%) and camphene (3.0–
5.6%). Fig. 1 represents the chemical structures of the most
commonly occurring major compounds in the volatile sec-
ondary metabolites of A. afra.
(b) Different plant parts used: Most A. afra oils analysed
were obtained from the aerial plant parts (Chagonda et al.,
Fig. 1. Chemical structures of the most commonly occurring major volatile secondary metabolites from Artemisia afra.
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et al., 2007). Analysis of oils obtained from different plant
parts showed that the chemical components varied
depending on the plant part used e.g. Goodson (1922)
found camphor, a wax ester, triacontane, scopoletin and
quebrachitol in the flowering tops of A. afra. Bohlmann
and Zdero (1972) revealed that the roots contained
isomeric coumarins and five acetylenes, while the aerial
parts contained thujone and umbelliferone-derivatives,
but no acetylenes. The same variation occurred in the
volatile secondary metabolite composition between the
leaves of A. afra (Mwangi et al., 1995) and the whole
plant (Worku and Rubiolo, 1996). The results showed that
the oil obtained from the leaves consisted mainly of 1,8-
cineole (67.4%), while yomogi alcohol (21.6–26.8%) and
artemisyl acetate (24.4–32.1%) predominated in the oil
extracted from the whole plant.
(c) Drying methods: Asekun et al. (2007) reported that the
yields and compositions of oil from A. afra varied
according to the drying method used. Yields obtained
were 0.18%, 0.88%, 1.54% and 1.88% for fresh, oven-
dried, air-dried and sun-dried material respectively.
They also found that artemisia ketone was present in
the oil extracted from the fresh material but was absentin the oil extracted from the air-dried and sun-dried
material.
(d) Variation within the natural population: Viljoen et al.
(2006) collected 16 individual A. afra samples from four
natural populations, Setibeng (Lesotho), Giant's Castle
(KwaZulu-Natal), Qwa-qwa (Free State) and Kliprivers-
berg (Gauteng) and found qualitative and quantitative
differences within and between populations.
6. Biological effect of A. afra extracts
Considering the many traditional uses, the plant has been
studied for various biological activities. These activities will be
discussed in the following paragraphs with their corresponding
references.
6.1. Biological activities
A. afra is rich in terpenes and is therefore likely to have
valuable biological activities. From the available literature the
results of conducted tests indicated that this plant has a broad
spectrum of inhibitory activity against the organisms listed in
Table 3. Most of the activities were expressed in zone of
inhibition, while relatively few studies determined the minimum
Table 3
Reported activities of extracts obtained from Artemisia afra against selected microorganisms.
Microorganism Minimum inhibitory
concentration (mg/ml)
Minimum inhibitory
percentage (%)
Diameter of zone
of inhibition (mm) a
IC50
(μg/ml)
Author
Gram-positive bacteria
Bacillus cereus – – 9.5±1.0 – Mangena and Muyima, 1999
B. subtilis 4.0 – 14.5±2.4 – Rabe and Van Staden, 1997;
Mangena and Muyima, 1999
Listeria monocytogenes – – 25.0±1.4 – Mangena and Muyima, 1999
Micrococcus luteus – – 12.0±0.0 – Mangena and Muyima, 1999
Mycobacterium smegmatis 1.6 – – – Mativandlela et al., 2008
M. tuberculosis na b – – – Mativandlela et al., 2008
Staphylococcus aureus 2.0 – 14.0±0.0 c
21.3±2.0 d
– Rabe and Van Staden, 1997; Mangena and
Muyima, 1999; Muyima et al., 2002;
Van Vuuren and Viljoen, 2006
S. aureus – N1 – – Huffman et al., 2002
S. aureus 1639 (Methicillin resistant) – 0.25 – – Huffman et al., 2002
S. epidermis 4.0 – 10.0±0.0 – Mangena and Muyima, 1999;
Rabe and Van Staden, 1997
Streptococcus pyogenes – – 28.0±0.0 – Mangena and Muyima, 1999
Gram-negative bacteria
Acinetobacter calcoaceticus – – 10.0±0.0 – Mangena and Muyima, 1999
A. lwoffii – – 11.0±1.4 – Mangena and Muyima, 1999
A. johnsonii – – 23.0±1.4 – Mangena and Muyima, 1999
Enterobacter aerogene – – 10.5±1.0 – Mangena and Muyima, 1999
E. cloacae – – 10.5±1.9 – Mangena and Muyima, 1999
Erwinia chrysanthemi – – 11.0±1.4 – Mangena and Muyima, 1999
E. carotovora – – 18.5±1.2 – Mangena and Muyima, 1999
Escherichia coli K12 – – 17.5±2.0 – Mangena and Muyima, 1999
E. coli (SR) e – – 9.5±1.2 – Mangena and Muyima, 1999
Proteus mirabilis – – 12.0±2.0 – Mangena and Muyima, 1999
Pseudomonas aeruginosa f – – 6.0±0.0 – Muyima et al., 2002
P. aeruginosa – N9.0 – – Huffman et al., 2002
P. aeruginosa – – 6.0±0.0 – Muyima et al., 2002
P. fluorescens – – 6.0±0.0 – Mangena and Muyima, 1999
Ralstonia picketti – – 21.7±2.9 – Muyima et al., 2002
Salmonella enteritidus – – 14.0±2.8 – Mangena and Muyima, 1999
S. newport – – 14.5±1.2 – Mangena and Muyima, 1999
S. poona – – 12.0±2.3 – Mangena and Muyima, 1999
S. thompson – – 13.5±1.4 – Mangena and Muyima, 1999
S. typhi – – 10.0±0.0 – Mangena and Muyima, 1999
S. typhimurium (SR) e – – 11.0±1.8 – Mangena and Muyima, 1999
S. typhimurium (WT) g – – 11.6±4.9 – Mangena and Muyima, 1999
Shigella flexneri – – 13.0±3.4 – Mangena and Muyima, 1999
S. sonnei – – 9.5±1.0 – Mangena and Muyima, 1999
Yersinia enterocolitica – – 15.5±2.5 – Mangena and Muyima, 1999
Fungi
Candida albicans – – 22.3±1.6 – Muyima et al., 2002
C. albicans – 0.25 – – Huffman et al., 2002
Crytococcus neoformans – 0.5 – – Huffman et al., 2002
Dekkera bruxellensis – – 12.7±0.7 – Mangena and Muyima, 1999
Hanseniaspora vinae – – 21.0±1.4 – Mangena and Muyima, 1999
Hyphopichia burtonii – – 19.5±1.9 – Mangena and Muyima, 1999
Pichia anomala – – 14.5±0.7 – Mangena and Muyima, 1999
P. fabianii – – 12.3±3.2 – Mangena and Muyima, 1999
P. jadinii – – 13.8±2.7 – Mangena and Muyima, 1999
Saccharomyces cerevisiae UOFS Y0149 – – 18.5±2.5 – Mangena and Muyima, 1999
S. cerevisiae UOFS Y150 – – 20.0±1.5 – Mangena and Muyima, 1999
S. cerevisiae UOFS Y0154 – – 22.3±2.8 – Mangena and Muyima, 1999
Torulaspora delbruckii UOFS Y0159 – – 12.0±0.0 – Mangena and Muyima, 1999
T. delbruckii UOFS Y160 – – 10.0±0.0 – Mangena and Muyima, 1999
Zygosaccharomyces bailii – – 11.5±0.6 – Mangena and Muyima, 1999
(continued on next page)
(continued on next page)
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Table 3 (continued )
Microorganism Minimum inhibitory
concentration (mg/ml)
Minimum inhibitory
percentage (%)
Diameter of zone
of inhibition (mm) a
IC50
(μg/ml)
Author
Protozoa
P. falciparum D6h – – – 9.0±0.5 i, j Gathirwa et al., 2007
P. falciparum D10 – – – 5.0 k Clarkson et al., 2004
P. falciparum Dd2 – – – 15.3 Kraft et al., 2003
P. falciparum PoW – – – 8.9 Kraft et al., 2003
P. falciparum W2 l – 4.0±1.0 i, j Gathirwa et al., 2007
Results are expressed with standard deviations only if included in the original publication.
a Antimicrobial activity of undiluted essential oil of A. afra was evaluated by diameter of zone of inhibition in millimeters (including disc diameter of 6 mm)
against selected microorganism;
b No activity at highest concentration tested;
c Data from Mangena and Muyima, 1999;
d Data from Muyima et al., 2002;
e Streptomycin resistant strain;
f Pseudomonas aeruginosa isolated from environment and identified by API identification system;
g Wild type;
h Chloroquine sensitive;
i The highest activity appeared in methanolic extract;
j High activity: IC50(10 μg/ml;
k High activity: IC50≤5 μg/ml;
l Chloroquine resistant.
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(MIP), or IC50 values. Not all of the publications provided
statistical data such as the standard deviations obtained.
Poswal and Witbooi (1997) found that, of the five plant
species evaluated, the oils of A. afra and Lavandula angustifolia
were the most effective against Pseudomonas syringae pv.
Syringae, while the A. afra extract was least active against
P. solanacearum. Different strains of the same species also
showed different susceptibilities to A. afra extracts. P. solana-
cearum Ps46 proved more susceptible than P. solanacearum
Ps62 to the plant oil. The activity of A. afra oil was determined
against different strains of yeasts. Eventually, Hanseniaspora
vinae and Saccharomyces cerevisiaewere the most susceptible to
the oil, while Zygosaccharomyces bailii andDekkera bruxellensis
were proved to be the least sensitive (Mangena and Muyima,
1999).
Rabe and Van Staden (1997) tested the antimicrobial ac-
tivities of the extracts of A. afra against Staphylococcus aureus,
S. epidermis and Bacillus subtilis, the results showed that the
lowest MIC was achieved against S. aureus. They also reported
that the majority of the antibacterial activity of A. afra extracts
was present in the methanol extracts instead of water extracts.
Mangena and Muyima (1999) also found that of 29 species of
bacteria and 12 strains of yeast tested, only three species of
bacteria (Escherichia coli, P. aeruginosa and P. fluorescens)
and one strain of yeast (Torulaspora delbruckii) did not show
obvious dose–effect relationship when three different con-
centrations of A. afra oil were used (undiluted, 1:1 and 1:2
dilutions). Muyima et al. (2002) did a similar experiment and
the results showed that in most cases only the highest con-
centrations of A. afra oil inhibited the tested bacteria, except
against P. aeruginosa ATCC 27853 and strains of P. aeruginosa
isolated from the environment. Asres et al. (2001) indicated that
the crude methanolic extract of A. afra did not inhibit Myco-
bacterium tuberculosis.Kraft et al. (2003) found that the lipophilic extracts of the
aerial parts of A. afra showed the highest activity against the
chloroquine-sensitive Plasmodium falciparum strain PoW and
against the chloroquine-resistant clone Dd2 of P. falciparum,
compared to the lipophilic extracts of Cussonia spicata, Clutia
hirsute, Vernonia natalensis, Parinari curatellifolia, Flueggea
virosa, Adenia gummifera, Hymenodictycon floribundum and
the hydrophilic extracts of all above species including A. afra
itself and V. colorata. They also indicated that the antiplasmo-
dial effect of A. afra was probably due to the additive or even
synergistic activity of the complex mixture of substances found
in the extract. Clarkson et al. (2004) reported that the dichlo-
romethane extract exhibited the strongest antiplasmodial
activity against P. falciparum D10 (IC50 value of 5 µg/ml)
compared to the dichloromethane/methanol (1:1), methanol and
water extracts (IC50 value of 7.3, 8.0 and N100.0 µg/ml,
respectively). Gathirwa et al. (2007) proved that the methanolic
extract of A. afra showed more activity against P. falciparum
D6 and P. falciparumW2 (IC50 values of 9.04±0.54 and 3.98±
0.98, respectively), compared to the water extract (IC50 values
of 11.23±1.98 and 4.65±0.64, respectively). In addition, the
P. berghei infected mice treated with the methanolic extract had
a longer survival time (19.21±3.57 days) than those treated
with the water extract (17.85±2.81). Both studies indicated that
the antiplasmodial compounds in this plant are more soluble in
lipophilic solvents than hydrophilic solvents. Jenett-Siems et al.
(2002) indicated that A. afra was not very suitable for anti-
plasmodial treatment because the activity of the isolated com-
pound (e.g. a sesquiterpene lactone) was lower than the toxicity
against ECV-304 cells. However, Kraft et al. (2003) discovered
that two types of compounds were responsible for the antiplasmo-
dial effect of this plant, including flavonoids (7-methoxyacacetin,
acacetin, genkwanin and apigenin) and sesquiterpene lactones
(1-desoxy-1α-peroxy-rupicolin A-8-O-acetate, rupicolin A-8-O-
acetate and 1α,4α-dihydroxybishopsolicepolide).
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standard forms of treatment for HIV positive patients (Mulhol-
land and Drewes, 2004). Positive results obtained suggest that
A. afra exhibits some antiviral activity or immune boosting
properties.
6.2. Spasmolytic properties
Mulatu and Mekonnen (2007) tested the traditional folk use
of A. afra for stomach pains and intestinal cramps. The results
showed that the ethanolic extract of A. afra leaves, significantly
reduced spontaneous rhythmic and agonist-induced contrac-
tions of isolated mouse duodenum and guinea pig ileum.
6.3. Cardiovascular effect
The aqueous A. afra extracts displayed a hypotensive effect
in vivo and a concentration-dependent biphasic effect on the heart
in vitro. Low concentrations induced an initial cardio stimulation
followed by cardio depression, while higher concentrations
mainly showed cardio depression. In addition, a compound iso-
lated fromA. afra, scopoletin, induced a dose-dependent decrease
in inotropic activity and a decrease in heart rate, especially at
higher doses (Guantai and Addae-Mensah, 1999).
6.4. Antioxidant activity
Artemisia afra has been used to treat various inflammatory
diseases such as rheumatism, fever and diabetes (Halliwell and
Gutteridge, 1989). It was shown that the anticoccidial potential
of this plant is also due to its antioxidant activity (Naidoo et al.,
2008). Burits et al. (2001) used a rapid TLC screening method
for the evaluation of the antioxidant activity of A. afra. It was
claimed that the volatile oils of A. afra could play a role as a
nonspecific donor for hydrogen atoms or electrons in the
diphenylpicrylhydrazyl assay and it was further shown to be an
effective hydroxyl radical scavenging agent in the deoxyribose
degradation assay. The oil of A. afra also showed antioxidant
potential in the bioassay for non-enzymatic lipid peroxidation in
liposomes. According to the results of various activity tests and
GC-MS analysis, the sesquiterpene, chamazulene, was sug-
gested to be responsible for the radical scavenging effect of the
oil.
6.5. Sedative and CNS-acting activities
Artemisia species have been proven to have anti-convulsive
and GABAA-benzodiazepine receptor-binding activity (Sayyah
et al., 2004; Salah and Jäger, 2005). Stafford et al. (2005)
discovered sedative and CNS-acting activities of A. afra
according to the GABAA-benzodiazepine receptor-binding
assay. The results showed that the ethanolic extract of the
plant had a good dose-dependent activity (binding % of 5.0±
0.9, 45.3±3.5 and 81.8±4.2 at concentrations of 0.455 mg/ml,
0.046 mg/ml and 0.005 mg/ml respectively). It was also claimed
that flavonoids were the active compounds related to the
sedative and CNS-acting activities.6.6. Antidepressant activity
According to the monoamine hypothesis, some transmit-
ters, such as serotonin, noradrenalin, dopamine, GABA and
L-glutamate, are related to depression (Rang et al., 1999).
Therefore, several antidepressants available on the market
today are based on selective inhibition of serotonin reuptake.
Nielsen et al. (2004) reported that the ethanolic extract of
A. afra showed a low affinity to the serotonin transporter
protein (Less than 50% [3H] citalopram binding at the highest
concentration of 5 mg/ml). The affinity of this extract exhibited
a concentration-dependent relationship, which indicated that
A. afra possesses a certain potential to treat depression.
6.7. Toxicity
Jenett-Siems et al. (2002) found that a sesquiterpene lactone
isolated from A. afra was responsible for the observed cyto-
toxicity. The crude ethanolic extract of A. afra also showed
cytotoxicity in Vero cells with an IC50 value of 113.0±2.05 µg/ml
(Mativandlela et al., 2008). Acute and chronic toxicity of this
plant was also exhibited through in vivo tests in rodents. In
the acute toxicity assay, single intraperitoneal injections (1.5–
5.5 g/kg) and single oral doses (2–24 g/kg) of an aqueous extract
ofA. afrawere administered to observe the toxicity of this plant in
rodents. The intraperitoneal route of administration induced a
regular dose-dependent increase in the mortality and incidence of
general behaviour adverse effects, while the oral route showed a
dose-independent result.Meanwhile, the LD50 of these two routes
of administration were found to be 2.45 and 8.96 g/kg,
respectively. A chronic toxicity assay was also performed in
rodents by administering oral doses of an A. afra extract (0.1 or
1 g/kg/day) for 3 months. The result showed that no significant
changes occurred in general behaviour, body weight, haemato-
logical and biochemical parameters, organ weights and morphol-
ogy of organs (Mukinda and Syce, 2007).
7. Quality control
Artemisia afra has been traditionally used to treat symptoms
which can be related to malaria. Although there are only few
scientific publications available to support this, a commercial
company is currently selling an A. afra product which they
claim to be effective in the treatment of malaria. The claim is
further supported by the fact that the activity of their product can
be ascribed to the well known antiplasmodial compound, arte-
misinin. Due to these claims a study was performed to establish
a quality control protocol and metabolomic differentiation
between A. afra and the well known A. annua (which contains
artemisinin). This study was conducted in order to establish a
rapid metabolomics approach and to carry out quality control on
these herbal formulations (Van der Kooy et al., 2008). The claim
that artemisinin (so far only found in A. annua) is responsible
for the antiplasmodial effects of A. afra was investigated and
disproved. The results indicated that these two plant species
(A. afra and A. annua) could easily be identified based on
their metabolomic profiles. The separation between the two
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misinin in the NMR spectrum. Additional LC-MS analysis also
demonstrated that artemisinin could not be detected in the
A. afra samples.
8. Discussion and conclusions
Artemisia afra is widely distributed in the southern parts of
Africa. It is therefore one of the most utilized plants in the African
ethnopharmacology. This review aimed at describing the different
uses of A. afra, either alone or in combination with different
substances or species, in treating various ailments. Themain focus
of this review was however to bring together all available
scientific research that has been conducted on this species. The
identification of the volatile secondary metabolites obtained from
this species received a lot of attention as is reflected by the number
of papers that has been published on this matter.
The differences in the chemical profiles of the volatile con-
stituents of A. afra can be ascribed to geographical variations,
different plant parts used, different sample preparation and
extraction methods and genetic differences within populations.
The obtained variation makes quality control of this species
extremely difficult. Although three of the above-mentioned
causes for variation can be controlled, the natural variation
between individuals cannot be controlled in the wild. Future
research should therefore focus on establishing reproducible
quality control methods in order to minimize the variation found
in the volatile secondary metabolites, but also the non-volatile
secondary metabolites, between individuals. In addition, all the
secondary metabolites reported in literature are listed in this
review in order to be able to conduct future dereplication studies.
Artemisia afra has also been tested against a multitude of
microorganisms as can be seen from Table 3. Future research
should however first focus on establishing quality control
protocols, followed by testing the extracts against the micro-
organisms which showed the highest sensitivities. Although
A. afra has been tested for its antiplasmodial activity (Jenett-
Siems et al., 2002; Kraft et al., 2003; Clarkson et al., 2004;
Gathirwa et al., 2007), this has not yet been fully demonstrated.
It has also been proven that this species does not contain the
antiplasmodial component, artemisinin (in detectable levels),
which occurs in A. annua (Van der Kooy et al., 2008). Due to
the traditional use and commercial claims that A. afra is ef-
fective as a prophylactic as well as treating uncomplicated
malaria, this aspect should be researched further. Research in this
area should focus on determining the antiplasmodial activity of
A. afra samples fromvarious regions aswell as at different growth
stages. If compared to the well known antiplasmodial plant,
A. annua, it was shown that the active component, artemisinin, is
present at its highest concentration just before flowering. The
concentration of this compound can fluctuate between 0.01%–
1.00% (Liu et al., 2006). If a similar antiplasmodial compound is
present inA. afra, the growth stage at which to produce an extract
to perform the bioassays, becomes extremely important.
Based on the data presented in this review it can be con-
cluded that A. afra might become a future flagship species for
TAM, if the problems associated with quality control could besolved and more importantly, if we can identify the active
component(s), especially the antiplasmodial secondary meta-
bolites, in this species.
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